Enzo Biochem (ENZ) Stock Price
Enzo Biochem Price
Over the last 19 years Enzo Biochem grew revenue by 18.4% annually, reaching 992.90 M USD. Earnings per share have declined at 30.0% per year over the last 5 years. For Enzo Biochem, the net margin of -0.8% is down versus 6.7% a few years ago. At today's price the dividend yield works out to roughly 18.20%.
Enzo Biochem stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Enzo Biochem business model & stock analysis
Frequently asked questions about Enzo Biochem
Enzo Biochem Inc is a life sciences and biotechnology company. Its business model encompasses the development, manufacturing, and commercialization of innovative diagnostic and research products. The company offers a diverse range of products and services catering to the life sciences industry. These include molecular diagnostics, immunohistochemistry, flow cytometry, and drug discovery research tools. Enzo Biochem Inc also operates clinical reference laboratories that provide a wide array of testing services. By leveraging its proprietary technology platforms, the company aims to facilitate advancements in personalized medicine and scientific research. Through collaborations and strategic partnerships, Enzo Biochem Inc strives to contribute to advancements in healthcare and improve patient outcomes.
Enzo Biochem Inc is primarily active in the life sciences and biotechnology industry.
The main competitors of Enzo Biochem Inc in the market include companies such as Thermo Fisher Scientific, Quidel Corporation, and Bio-Rad Laboratories.
Enzo Biochem Inc, founded in 1976, is a leading life sciences and biotechnology company based in New York. It specializes in the development, production, and commercialization of innovative diagnostic and research products worldwide. Enzo Biochem is known for its cutting-edge technology platforms, including gene regulation, therapeutics, and molecular diagnostic systems. The company's focus extends to areas such as biomarkers, infectious diseases, and cancer diagnostics. With a strong history of innovation and a commitment to delivering high-quality products and services, Enzo Biochem continues to play a significant role in advancing the field of life sciences and improving patient care.
Enzo Biochem Inc has achieved several significant milestones throughout its history. In 1976, the company was founded by Dr. Elazar Rabbani and developed innovative technologies for the life sciences and biotechnology sectors. In 1985, Enzo introduced the first commercial oligo synthesizer, revolutionizing DNA research. The company continued to expand its portfolio and in the late 1990s, launched diagnostic products for molecular oncology and genetics. Enzo has also successfully obtained numerous patents for its inventions. Over the years, Enzo Biochem Inc has established itself as a leading player in the life sciences industry with its strong commitment to innovation, research, and development.
Enzo Biochem Inc is primarily present in the United States.
Enzo Biochem Inc represents the values of innovation, excellence, and integrity. The company is committed to advancing scientific research and delivering cutting-edge diagnostic and therapeutic solutions. Enzo Biochem Inc embraces a corporate philosophy centered around quality, accuracy, and collaboration. They strive to provide accurate and reliable products and services to enable healthcare professionals to improve patient outcomes. With a strong focus on research and development, Enzo Biochem Inc aims to address significant unmet medical needs and drive advancements in the field of life sciences.
5 analysts currently rate the Enzo Biochem stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Enzo Biochem to generate revenue of 107.03 M USD and earnings per share of -0.07 USD.
Converted at the current exchange rate, the Enzo Biochem share trades at 0.49 EUR (0.55 USD).
The Enzo Biochem share (ENZ) is listed on 6 stock exchanges, including: NYSE (ENZ), London (0IHV.L), SIX (Zürich) (EZB.SW), Frankfurt (EZB.F), München (EZB.MU), Düsseldorf (EZB.DU).
Enzo Biochem Inc is a leading company in the field of life science research, offering a wide range of products and services. The company operates in three main business areas: life sciences, clinical labs, and therapeutics. In the life sciences field, the company provides researchers with a comprehensive range of products and services to better understand the fundamentals of life, including enzymes and proteins, genetic engineering, and immunology. In the clinical lab services area, Enzo Biochem Inc offers specialized testing procedures and preparation technologies to its customers, operating multiple clinical labs in New York and New Jersey. The company also develops a wide range of therapeutics for the treatment of diseases and disorders, based on genetic and biochemical technologies to understand disease mechanisms and develop more effective treatment methods. Enzo Biochem Inc places a strong emphasis on innovation, continuously investing in research and development to provide customers with value-added technologies and methods. Additionally, the company is committed to sustainability and environmental friendliness, developing technologies and products that meet customer requirements while minimizing environmental impact. Overall, Enzo Biochem Inc provides customers with a comprehensive range of products and services to address the challenges of life science research and development, with a focus on innovation and customer satisfaction.
The expected revenue of Enzo Biochem is 107.03 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Enzo Biochem is -9.72 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Enzo Biochem is currently -7.85. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Enzo Biochem stock.
The price-to-sales ratio (P/S) of Enzo Biochem is currently 0.71. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Enzo Biochem stock.
The Eulerpool Quality Score for Enzo Biochem is 5/10.
The ISIN of Enzo Biochem is US2941001024. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Enzo Biochem is 865607. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Enzo Biochem is ENZ. The ticker symbol is used to trade Enzo Biochem shares on the stock exchange.
Enzo Biochem stock
Enzo Biochem Peer Group
Enzo Biochem Ticker
Enzo Biochem FIGI
All fundamentals and in-depth analysis of Enzo Biochem
Our stock analysis for Enzo Biochem stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Enzo Biochem. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.